MiR-146a and miR-196a-2 polymorphisms are associated with hepatitis virus-related hepatocellular cancer risk: a meta-analysis.
Previous studies have investigated the role of miR-146a rs2910164 and miR-196a-2 rs11614913 polymorphisms in hepatocellular carcinoma (HCC) susceptibility, but the results are contradictory and few specifically studied hepatitis virus-related HCC. Therefore, we conducted a meta-analysis to evaluate the association between these two polymorphisms and hepatitis virus-related HCC risk. We performed a systematical search in EMBASE, PubMed, Web of Science, CNKI and Wanfang databases as of 25th November, 2016. Finally, we assessed 14 studies involving 3852 cases and 5275 controls. Our results suggest that rs2910164 has a significant association with increased hepatitis virus-related HCC risk in allelic, homozygous, heterozygous, and dominant models (CG+GG vs. CC: OR=1.22, 95% CI=1.06-1.39, P=0.004), particularly in Chinese and HBV-related HCC subgroups. Conversely, rs11614913 was associated with lower hepatitis virus-related HCC risk in the overall analysis under allelic (T vs. C: OR=0.85, 95% CI=0.74-0.98, P=0.02), homozygous, dominant and recessive models. Subgroup analyses showed decreased risk in Chinese, HBV- and HCV-related HCC. In conclusion, miR-146a C>G (rs2910164) can increase HBV-related HCC risk while miR-196a-2 C>T (rs11614913) may decrease the risk of HBV- and HCV-related HCC, especially in the Chinese population. Further, large-scale studies including other races are required to confirm these findings.
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Tian
T
Tian
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Meng
M
Wang
Department of Biochemistry and Molecular Medicine, The George Washington University Medical School, Washington, DC 20037, USA.
Wenge
W
Zhu
Department of Anesthesia, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Zhi-Ming
ZM
Dai
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Shuai
S
Lin
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Peng-Tao
PT
Yang
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xing-Han
XH
Liu
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Kang
K
Liu
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Yu-Yao
YY
Zhu
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Yi
Y
Zheng
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Meng
M
Liu
Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Zhi-Jun
ZJ
Dai
D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000821:virology; D020022:Genetic Predisposition to Disease; D006505:Hepatitis / Q000150:complications*; D006518:Hepatitis Viruses; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics* / Q000821:virology; D035683:MicroRNAs / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
C542542:MIRN146 microRNA, human; C542543:MIRN196 microRNA, human; D035683:MicroRNAs
hepatitis virus-related hepatocellular carcinoma; meta-analysis; microRNA; single nucleotide polymorphism